| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
Rivaroxaban D4 targets the same enzyme as its unlabeled parent drug, which is coagulation factor Xa (FXa), a key serine protease in the blood coagulation cascade. Rivaroxaban is a highly potent and direct FXa inhibitor. By binding to and inhibiting FXa, it prevents the conversion of prothrombin to thrombin, thereby reducing the formation of fibrin clots. The deuterium labeling provides a mass shift for analytical detection without affecting the compound's pharmacological target.
|
|---|---|
| ln Vitro |
Rivaroxaban D4 is primarily used as an internal standard for analytical purposes rather than for its pharmacological activity. Rivaroxaban itself demonstrates a strong gain in anti-FXa potency with an IC50 of 0.7 nM and a Ki of 0.4 nM. The in vitro potency of the deuterated analog is expected to be identical to the parent compound, but its use in biological assays is typically limited to serving as a tracer or standard.
|
| ln Vivo |
In vivo studies using Rivaroxaban D4 are primarily pharmacokinetic. The deuterium-labeled compound can be co-administered with unlabeled Rivaroxaban to accurately study absorption, distribution, metabolism, and excretion (ADME). It is used as an internal standard in bioequivalence studies and method validation for regulatory submissions. Its in vivo anticoagulant effects are expected to be similar to those of Rivaroxaban, which is used to treat and prevent thromboembolic disorders.
|
| Enzyme Assay |
In vitro enzyme/receptor binding (non-cell) assays for Rivaroxaban D4 are typically performed as part of analytical method validation. The compound is dissolved in an appropriate solvent and spiked into biological matrices at known concentrations to serve as an internal standard. Calibration curves are generated by plotting the peak area ratio of Rivaroxaban to Rivaroxaban D4 against the concentration of Rivaroxaban. It is not typically used in pharmacological enzyme assays, where the unlabeled compound is preferred.
|
| Cell Assay |
For in vitro cell-based assays, Rivaroxaban D4 can be used in studies investigating the compound's cellular effects, though its primary use is as an analytical internal standard. Cells relevant to thrombosis research can be treated with the compound, and its effects on coagulation factors can be measured. However, due to its role as an internal standard, it is more frequently used in the analytical quantification of the parent drug from cell culture supernatants.
|
| Animal Protocol |
In vivo animal studies with Rivaroxaban D4 are primarily pharmacokinetic. The compound is administered orally or intravenously to rodents, and blood samples are collected at predetermined time points. Plasma concentrations of both labeled and unlabeled Rivaroxaban are analyzed by LC-MS/MS using Rivaroxaban D4 as the internal standard. Pharmacodynamic effects, such as anticoagulation, can be evaluated in appropriate models, though the labeled compound's primary role is analytical.
|
| ADME/Pharmacokinetics |
Rivaroxaban D4 (CAS: 1132681-38-9) has a molecular weight of 439.91 g/mol and a molecular formula of C19H14D4ClN3O5S. The compound features four deuterium atoms on the phenyl ring. It is supplied as a high-purity reference standard for research and analytical applications. Storage is typically at 2-8°C. The D4 label provides a +4 Da mass shift, ensuring clear resolution from the parent compound in mass spectrometric analyses.
|
| Toxicity/Toxicokinetics |
Rivaroxaban D4 is used in very small quantities as an analytical internal standard and does not pose significant toxicity risks under normal handling. As a deuterium-labeled analog of an approved anticoagulant, it is expected to have a similar pharmacological profile, but toxicology studies are not typically performed on the labeled compound. Rivaroxaban is generally well-tolerated, with bleeding being the most significant adverse effect.
|
| References |
|
| Additional Infomation |
Rivaroxaban D4 is a stable isotope-labeled internal standard for the direct FXa inhibitor Rivaroxaban (BAY 59-7939). It is a critical reagent for pharmaceutical research, enabling accurate quantification in biological samples for pharmacokinetic, metabolic, and bioanalytical studies. The compound is also known as BAY 59-7939-d4. It is not intended for human therapeutic use and is for research and analytical use only.
|
| Molecular Formula |
C19H14D4CLN3O5S
|
|---|---|
| Molecular Weight |
439.906
|
| Exact Mass |
439.091
|
| CAS # |
1132681-38-9
|
| Related CAS # |
Rivaroxaban;366789-02-8
|
| PubChem CID |
25255944
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.04
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
29
|
| Complexity |
645
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
[2H]C1=C(C(=C(C(=C1N2CCOCC2=O)[2H])[2H])N3C[C@@H](OC3=O)CNC(=O)C4=CC=C(S4)Cl)[2H]
|
| InChi Key |
KGFYHTZWPPHNLQ-UJCPGTITSA-N
|
| InChi Code |
InChI=1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1/i1D,2D,3D,4D
|
| Chemical Name |
5-chloro-N-[[(5S)-2-oxo-3-[2,3,5,6-tetradeuterio-4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl]methyl]thiophene-2-carboxamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2732 mL | 11.3660 mL | 22.7319 mL | |
| 5 mM | 0.4546 mL | 2.2732 mL | 4.5464 mL | |
| 10 mM | 0.2273 mL | 1.1366 mL | 2.2732 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
